All I wanted to do was die. If I could just clean out my gutters and “accidentally” fall off the roof, all of my problems would be solved. My misery would be over.
An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.
Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share pric
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.